
Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name The Duberstein Group, Inc.		
2. Registrant Address	OC 20037 USA	
3. Principal Place of Business (if different from line 2)		
City State/Zip (or Country)		
4. Contact Name Telephone E-mail John W. Angus, III 202-728-1100	(optional) 5. Senate ID #	
7. Client Name Self Pfizer Inc.	6. House ID # 31811044	
9. Check if this filing amends a previously filed version of this 10. Check if this is a Termination Report >> Termination INCOME OR EXPENSES - Complete Either	1 Date 11. No Lobbyii	
12. Lobbying Firms	13. Organizations	
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this repo period were:	
Less than \$10,000	Less than \$10,000 □	
\$10,000 or more >> \$\frac{\$60,000.00}{\text{lncome (nearest \$20,000)}}	\$10,000 or more	
Provide a good faith estimate, rounded to the nearest	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of	
\$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity	☐ Method A. Reporting amounts using LDA definition	
for lobbying activities on behalf of the client).	☐ Method B. Reporting amounts under section 60336 the Internal Revenue Code	
	☐ Method C. Reporting amounts under section 162(€ Internal Revenue Code	

Signature		Date .	2/17/2004	
Printed Name and Title	John W. Angus, III - Senior Vice President & GC			_ Pag

00000603311

Reg	istrant Name:	The Duberstein Group, Inc.	
Clie	nt Name:	Pfizer Inc.	
enga	iged in lobbyin		to reflect the general issue areas in which the registrant ag period. Using a separate page for each code, provide.
15.	General issue	area code <u>GOV</u> (one per page)	
16.	S.1125, FAI Fairness in A	oying issues Asbestos in America Act of 2003, Asbesto R Act of 2003 Asbestos Injury Resolution Act of 2003, Asbestos Claims Criteria and Compensation	Asbestos Trust Fund
17.		Congress and Federal agencies contacted presentatives	☐ Check if None
18.	Name of each	n individual who acted as a lobbyist in this	issue area
	Name		Covered Official Position (if applicable)
	Angus, III, J	ohn W.	
	Berman, Mi	chael S.	
	Champlin, S	teven M.	
	Gandy, Hen	ry M.	
	Meyer, Dani	iel	

★ Check if None

19. Interest of each foreign entity in the specific issues listed on line 16 above

Signature		Date <u>2/17/2004</u>	
Printed Name and Title	John W. Angus, III - Senior Vice President & GC		Pag

00000603312

Regi	istrant Name:	The Duberstein Group, Inc.		
Clie	nt Name:	Pfizer Inc.		
enga	aged in lobbyin		y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide	
15.	General issue	area code MMM (one per page)		
16. Specific Lobbying issues H.R.1, Medicare Prescription Drug and Modernization Act of 2003, Medicare prescription drug to f prescription drugs H.R.2473, Medicare Prescription Drug and Modernization Act of 2003, Medicare prescription drugs H.R.810, Medicare Regulatory and Contracting Reform Act of 2003, Medicare prescription drug of prescription drugs S.1, Prescription Drug and Medicare Improvement Act of 2003, Medicare prescription drug bene prescription drugs				
17.		Congress and Federal agencies contacted presentatives Louse	☐ Check if None	
18.	Name of each	n individual who acted as a lobbyist in this	issue area	
	Name		Covered Official Position (if applicable)	
	Angus, III, J	John W.		
	Berman, Mi	chael S.		
	Champlin, S	teven M.		
	Duberstein,	Kenneth M.		
	Gandy, Hen	ry M.	·	
	Meyer, Dan	iel		
				

Filing #453fa1e7-9679-4133-97c4-ea46ea04eff9 - Page 5 of 8

M Check if None

19. Interest of each foreign entity in the specific issues listed on line 16 above

Signature		Date <u>2/17/2004</u>	
Printed Name and Title	John W. Angus, III - Senior Vice President & GC		_ Pag

٦١١٦	nt Name: Pfizer Inc.	
enga		as necessary to reflect the general issue areas in which the registrant g the reporting period. Using a separate page for each code, provide (s) as needed.
15.	General issue area code PHA (o	ne per page)
16.	Modernization Act of 2003, Drug reimportation as Act of 2003, Drug reimportation ent, Food and Drug Administration, and Related Agencies Appropropropropropropropropropropropropro	
17.	House(s) of Congress and Federal agencies House of Representatives	contacted Check if None
18.	Name of each individual who acted as a lob	1
18.	Name	Obyist in this issue area Covered Official Position (if applicable)
18.	Name Angus, III, John W.	1
18.	Name Angus, III, John W. Berman, Michael S.	1
18.	Name Angus, III, John W.	1
18.	Name Angus, III, John W. Berman, Michael S.	1
18.	Name Angus, III, John W. Berman, Michael S. Champlin, Steven M.	Covered Official Position (if applicable)
18.	Name Angus, III, John W. Berman, Michael S. Champlin, Steven M. Duberstein, Kenneth M.	Covered Official Position (if applicable)

Signature WW PW	Date .	2/17/2004	
Printed Name and Title John W. Angus, III - Senior Vice President & GC			_ Pag